Collectively, advancing PAI-1-directed therapies from experimental strategies to clinical application represents a compelling opportunity to overcome immune resistance, mitigate metastatic progression, and improve survival outcomes for patients with otherwise refractory skin cancers. This evidence concerns the gene SERPINE1 and skin cancer.